Pharmaceuticals, Biotechnology and Life Sciences
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion of a €32 million Series B financing round.
Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration (FDA) and Health Canada have approved INQOVI® (decitabine and cedazuridine) tablets. The three companies are all part of the Otsuka group of companies.
Arcus Biosciences, an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer
Tenax Therapeutics in $8 million registered direct and pipe offerings priced at the market under Nasdaq rules
Sinovac Biotech’s partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines, has reached a milestone as it moved one step further to our commitment to developing vaccines for global use after getting the approval for Phase 3 trial from Brazilian National Regulatory Agency, Anvisa.
Vetter and Rentschler Biopharma have announced joining forces to boost their services and along the biopharmaceutical value chain.
Abivax has treated the first patient in its Phase 2b/3 study of ABX464 in COVID-19 patients at the University Hospital Center in Nice, France (CHU Nice) in a randomized, double-blind, placebo-controlled study, to see the the effects of early treatment in 1034 Covid-19 older or high-risk patients.
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, received the approval from the U.S. Food & Drug Administration (FDA) for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to test intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).
Remdevisir has become a popular word these days, along with Covid-19, Coronavirus, the city of Wuhan, and for a good reason. The headline in all the news, the pricing of remdevisir, has been flooding the internet, and pretty much the TV.
NuvOx Pharma ensured the continuation of Phase 2 clinical trial of its NanO2 in Covid-19 patients with acute hypoxic respiratory failure, as it got No Objection Letter from Health Canada.